Frimpong Clinical Research Service Doylestown, PA - 18901

Frimpong Clinical Research Service is categorized under Medical Research in Doylestown, PA and active since 1992.

Frimpong Clinical Research Service was established in 1992, and today employs 1 to 4, earning Unknown per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 5417115 by the NAICS.

If you are seeking more information, feel free to contact Nesba Frimpong, Owner at the company’s single location by writing to 76 Radcliff Drive, Doylestown, Pennsylvania PA 18901 or by phoning (215) 340-2777. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Frimpong Clinical Research Service
Contact Person: Nesba Frimpong, Owner
Address: 76 Radcliff Drive, Doylestown, Pennsylvania 18901
Phone Number: (215) 340-2777
Annual Revenue (USD): Unknown
Founded: 1992
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Medical Research
SIC Code: 8733
NAICS Code: 5417115
Share This Business:

Frimpong Clinical Research Service was started in 1992 to provide professional Medical Research under the SIC code 8733 and NAICS code 5417115. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.

Feel free to contact Nesba Frimpong, Owner for inquiries that concern Frimpong Clinical Research Service by calling the company number (215) 340-2777, as your correspondence is most welcome. Additionally, the physical location of the single location of Frimpong Clinical Research Service can be found at the coordinates 40.287754,-75.146571 as well as the street address 76 Radcliff Drive in Doylestown, Pennsylvania 18901.

For its online presence, you may visit Frimpong Clinical Research Service’s website at and engage with its social media outlets through on Twitter and on Facebook.